SI20149B - Pharmaceutical compositions of tizoxanide and nitazoxanide - Google Patents
Pharmaceutical compositions of tizoxanide and nitazoxanide Download PDFInfo
- Publication number
- SI20149B SI20149B SI9820037A SI9820037A SI20149B SI 20149 B SI20149 B SI 20149B SI 9820037 A SI9820037 A SI 9820037A SI 9820037 A SI9820037 A SI 9820037A SI 20149 B SI20149 B SI 20149B
- Authority
- SI
- Slovenia
- Prior art keywords
- active ingredient
- composition according
- particle size
- pharmaceutical composition
- formula
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 27
- YQNQNVDNTFHQSW-UHFFFAOYSA-N acetic acid [2-[[(5-nitro-2-thiazolyl)amino]-oxomethyl]phenyl] ester Chemical compound CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 YQNQNVDNTFHQSW-UHFFFAOYSA-N 0.000 title claims 2
- 229960002480 nitazoxanide Drugs 0.000 title claims 2
- FDTZUTSGGSRHQF-UHFFFAOYSA-N Desacetyl-nitazoxanide Chemical group OC1=CC=CC=C1C(=O)NC1=NC=C([N+]([O-])=O)S1 FDTZUTSGGSRHQF-UHFFFAOYSA-N 0.000 title 1
- 239000002245 particle Substances 0.000 claims abstract 39
- 239000002253 acid Substances 0.000 claims abstract 16
- 150000001875 compounds Chemical class 0.000 claims abstract 14
- 239000013543 active substance Substances 0.000 claims abstract 3
- 239000004480 active ingredient Substances 0.000 claims 32
- 239000000203 mixture Substances 0.000 claims 21
- 239000003979 granulating agent Substances 0.000 claims 6
- 239000007787 solid Substances 0.000 claims 5
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 5
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims 4
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 4
- 239000002552 dosage form Substances 0.000 claims 4
- 239000001630 malic acid Substances 0.000 claims 4
- 235000011090 malic acid Nutrition 0.000 claims 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 241001126309 Fasciolopsis Species 0.000 claims 2
- 241001491880 Heterophyes Species 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 241001660197 Metagonimus Species 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- 229930006000 Sucrose Natural products 0.000 claims 2
- 208000004938 Trematode Infections Diseases 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000003071 parasitic effect Effects 0.000 claims 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 241000223936 Cryptosporidium parvum Species 0.000 claims 1
- 241000205707 Cystoisospora belli Species 0.000 claims 1
- 241000577452 Dicrocoelium Species 0.000 claims 1
- 241000577456 Dicrocoelium dendriticum Species 0.000 claims 1
- 241000596569 Encephalitozoon intestinalis Species 0.000 claims 1
- 241000204939 Fasciola gigantica Species 0.000 claims 1
- 241000242711 Fasciola hepatica Species 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 206010023076 Isosporiasis Diseases 0.000 claims 1
- 229920000881 Modified starch Polymers 0.000 claims 1
- 241000186367 Mycobacterium avium Species 0.000 claims 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims 1
- 241000242678 Schistosoma Species 0.000 claims 1
- 241000242683 Schistosoma haematobium Species 0.000 claims 1
- 241000242687 Schistosoma intercalatum Species 0.000 claims 1
- 241000242677 Schistosoma japonicum Species 0.000 claims 1
- 241000242680 Schistosoma mansoni Species 0.000 claims 1
- 241001520868 Schistosoma mekongi Species 0.000 claims 1
- 241000242541 Trematoda Species 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 229960000541 cetyl alcohol Drugs 0.000 claims 1
- 125000005456 glyceride group Chemical group 0.000 claims 1
- 239000006194 liquid suspension Substances 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 235000019426 modified starch Nutrition 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 239000008253 pharmaceutical paste Substances 0.000 claims 1
- 235000015067 sauces Nutrition 0.000 claims 1
- 239000002562 thickening agent Substances 0.000 claims 1
- 239000000080 wetting agent Substances 0.000 claims 1
- 208000001388 Opportunistic Infections Diseases 0.000 abstract 1
- 241000869417 Trematodes Species 0.000 abstract 1
- 230000001010 compromised effect Effects 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Claims (40)
- Τ ··> 1 " ' ” " " FARMACEVTSKI SESTAVKI TIZOKSANIDA IN NITAZOKSANIDA PATENTNI ZAHTEVKI 1. Farmacevtski sestavek za oralno dajanje ki vsebuje učinkovito količino učinkovine z velikostjo trdnih delcev pod 200 μίτι spojine po formuli IIpri čemer je srednja velikost navedenih delcev učinkovine nad 10 pm.
- 2. Sestavek po zahtevku 1, značilen po tem, da je srednja velikost navedenih delcev učinkovine med 10 in 100 pm.
- 3. Sestavek po zahtevku 1, značilen po tem, da je srednja velikost navedenih delcev učinkovine med 20 in 50 pm.
- 4. Sestavek po zahtevku 1, značilen po tem, da ima pod 10 mas.% navedenih delcev učinkovine velikost delcev nad 100 pm.
- 5. Sestavek po zahtevku 1, značilen po tem, da ima vsaj 50 mas.% navedenih delcev učinkovine velikost delcev pod 50 pm.
- 6. Sestavek po zahtevku 2, značilen po tem, da ima pod 10 mas.% navedenih delcev učinkovine velikost delcev pod 5 pm. 2 ο > ^ Ο -» ο 2 ο > ^ Ο -» ο Λ ·> Τ ·..> Λ·»-) > » ι > :» ι ·> > ) )
- 7. Sestavek po zahtevku 1, značilen po tem, da obsega navedeni sestavek nadalje vsaj še eno farmacevtsko sprejemljivo kislino.
- 8. Sestavek po zahtevku 7, značilen po tem, da je navedena farmacevtsko sprejemljiva kislina izbrana iz skupine, ki obsega citronsko, glutaminsko, jantarno, etansulfonsko, ocetno, vinsko, askorbinsko, metansulfonsko, fumarno, adipinsko, jabolčno kislino ter njihove zmesi.
- 9. Sestavek po zahtevku 7, značilen po tem, da je navedena učinkovina v obliki trdnih delcev z velikostjo delcev pod 200 pm in srednjo velikost delcev nad 10 pm, in da je razmerje med maso farmacevtsko sprejemljive kisline/maso navedenih trdnih delcev med 0.01 in 0.5.
- 10. Sestavek po zahtevku 9, značilen po tem, da je razmerje med maso farmacevtsko sprejemljive kisline/maso navedenih trdnih delcev učinkovine med 0.03 in 0.2.
- 11. Uporaba farmacevtskega sestavka, ki vsebuje kot učinkovino najmanj eno spojino, izbrano iz skupine, ki obstaja iz spojine s formulo (I)in spojine s formulo (II) N O - CO - CH N02 S Λ NH—CO7 V (II) 3 3 Ο ,1 «ϊ ^ Ο > τ > -> “> ·;1 t οο ίο η η ^ mi Ο ,* ) 9 '> ) > -» 9 ι > Ί > Λ ·Ί > -J 1 ·) *> ' ' ·> Τ ,11 za pripravo zdravila za zdravljenje imunsko prizadetega sesalca okuženega z mikroorganizmom, izbranim iz skupine, ki obstaja iz Cryptosporidium parvum, Isospora belli, Enterocytzoon bieneusi, Encephalitozoon intestinalis, Mycobacterium tuberculosis, Mycobacterium avium intracellulare, Pneumocystis carinil in Toxoplasma gondii.
- 12. Uporaba farmacevtskega sestavka po zahtevku 11, značilna po tem, da je navedena učinkovina v obliki delcev s srednjo velikostjo delcev med 10 in 200 pm.
- 13. Uporaba farmacevtskega sestavka po zahtevku 11, značilna po tem, da navedena učinkovina v obliki delcev s srednjo velikostjo delcev med 20 in 50 pm.
- 14. Uporaba farmacevtskega sestavka po zahtevku 11, značilna po tem, da obsega navedeni farmacevtski sestavek nadalje vsaj še eno farmacevtsko sprejemljivo kislino.
- 15. Uporaba farmacevtskega sestavka po zahtevku 14, značilna po tem, da je navedena farmacevtsko sprejemljiva kislina izbrana iz skupine, ki obsega citronsko, glutaminsko, jantarno, etansulfonsko, ocetno, vinsko, askorbinsko, metansulfonsko, fumarno, adipinsko, jabolčno kislino ter njihove zmesi.
- 16. Uporaba farmacevtskega sestavka po zahtevku 11, značilna po tem, da je navedena učinkovina spojina s formulo (I).
- 17. Uporaba farmacevtskega sestavka po zahtevku 11, značilna po tem, da je navedena učinkovina spojina s formulo (II).
- 18. Uporaba farmacevtskega sestavka po zahtevku 11, značilna po tem, da je navedeni sesalec človek in je navedena učinkovina aplicirana v množini od 500 do 2000 mg dnevno. 4 3 Ο on-* ο j ο ο ί> ο ο ο ο ο ο ο η > η η η η ο η ο η "* * θ'*) > -> ·*
- 19. Uporaba farmacevtskega sestavka po zahtevku 18, značilna po tem, da je navedena učinkovina aplicirana v množini od 1000 do 1500 mg dnevno.
- 20. Uporaba farmacevtskega sestavka, ki vsebuje kot učinkovino najmanj eno spojino, izbrano iz skupine, ki obstaja iz spojine s formulo (I)in spojine s formulo (II) O - CO - CH n-,N v 3 NH—CONO, A (ID za pripravo zdravila za zdravljenje parazitske okužbe s trematodo, izbrano iz skupine, ki obstaja iz Schistosoma, Fasciola, Fasciolopsis, Dicrocoelium, Heterophyes in Metagonimus.
- 21. Uporaba farmacevtskega sestavka, ki vsebuje kot učinkovino najmanj eno spojino, izbrano iz skupine, ki obstaja iz spojine s formulo (I) NONH— CO(I) o O 10 11 .·> -> > -·» > -v ' ''>> > ) » ' O .) > -> ί Λ » -.1 in spojine s formulo (II) N Λ O - CO - CH no2 S nh—co(II) za pripravo zdravila za zdravljenje parazitske okužbe s trematodo, izbrano iz skupine, ki obstaja iz Schistosoma mansoni, Schistosoma haematobium, Schistosoma mekongi, Schistosoma japonicum, Schistosoma intercalatum; Fasciola hepatica, Fasciola gigantica, Fasciolopsis biski, Dicrocoelium dendriticum, Heterophyes hetemphyes in Metagonimus yokogawa.
- 22. Uporaba farmacevtskega sestavka po zahtevku 21, značilna po tem, da je navedena učinkovina v obliki delcev s srednjo velikostjo delcev med 10 in 200 μιτι.
- 23. Uporaba farmacevtskega sestavka po zahtevku 22, značilna po tem, da je navedena učinkovina v obliki delcev s srednjo velikostjo delcev med 20 in 50 pm.
- 24. Uporaba farmacevtskega sestavka po zahtevku 21, značilna po tem, da obsega navedeni farmacevtski sestavek nadalje vsaj še eno farmacevtsko sprejemljivo kislino.
- 25. Uporaba farmacevtskega sestavka po zahtevku 24, značilna po tem, da je navedena farmacevtsko sprejemljiva kislina izbrana iz skupine, ki obsega citronsko, glutaminsko, jantarno, etansulfonsko, ocetno, vinsko, askorbinsko, metansulfonsko, fumarno, adipinsko, jabolčno kislino ter njihove zmesi. 6 » ·>ο ^ 3 Λ "> -> D ·Ί 6 » ·>ο ^ 3 Λ "> -> D ·Ί Ο > Λ
- 26. Uporaba farmacevtskega sestavka po zahtevku 24, značilna po tem, da je razmerje med maso farmacevtsko sprejemljive kisline/maso navedenih delcev učinkovine med 0.01 in 0.5.
- 27. Uporaba farmacevtskega sestavka po zahtevku 21, značilna po tem, da je navedena učinkovina spojina s formulo (I).
- 28. Uporaba farmacevtskega sestavka po zahtevku 21, značilna po tem, da je navedena učinkovina spojina s formulo (II).
- 29. Farmacevtska pasta za zunanjo aplikacijo, značilna po tem, da navedena pasta vsebuje učinkovito količino učinkovine z velikostjo trdnih delcev pod 200 μηι spojine po formuli IIpri čemer imajo navedeni delci velikost pod 200 μιτι in srednjo velikost delcev nad 10 μιτι ; - najmanj eno omakalo; - najmanj en dodatek izbran iz skupine iz skupine, ki obstaja iz cetil alkohola, gliceridnih derivatov, propilen glikola in njihovih zmesi; - najmanj eno zgoščevalo.
- 30. Farmacevtski sestavek za oralno aplikacijo ki vsebuje učinkovito količino učinkovine z velikostjo trdnih delcev pod 200 μιτι spojine po formuli IIpri čemer je srednja velikost navedenih delcev učinkovine nad 10 pm; in - najmanj eno granulirno sredstvo.
- 31. Sestavek po zahtevku 30, značilen po tem, da je navedeno granulirno sredstvo izbrano iz skupine, ki obstaja iz polivinilpirolidona, vode, alkohola, saharoze, hidroksil celuloze, in njihovih zmesi.
- 32. Sestavek po zahtevku 30, značilen po tem, da obsegajo navedeni granulirani delci trdne učinkovine vsaj še eno farmacevtsko sprejemljivo kislino.
- 33. Sestavek po zahtevku 31, značilen po tem, da je navedena farmacevtsko sprejemljiva kislina izbrana iz skupine, ki obsega citronsko, glutaminsko, jantarno, etansulfonsko, ocetno, vinsko, askorbinsko, metansulfonsko, fumarno, adipinsko, jabolčno kislino ter njihove zmesi.
- 34. Sestavek po zahtevku 32, značilen po tem, da je razmerje med maso farmacevtsko sprejemljive kisline/maso navedene učinkovine med 0.01 in 0.5.
- 35. Dozirna oblika za oralno aplikacijo ki vsebuje učinkovito količino učinkovine z velikostjo trdnih delcev pod 200 pm spojine po formuli II NONH—co O - CO - CH * 3 '/ v (II) 8 > 'i > > O 1 » o >rt 1 Λ pri čemer je srednja velikost navedenih delcev učinkovine nad 10 μΐη; - najmanj eno omakalno sredstvo; in - najmanj en škrobni derivat.
- 36. Dozirna oblika po zahtevku 35, značilen po tem, da nadalje obsega vsaj še eno farmacevtsko sprejemljivo kislino.
- 37. Dozirna oblika po zahtevku 35, značilen po tem, da so navedeni delci učinkovine granulirani v prisotnosti granulirnega sredstva, ki vsebuje od 2 do 99.97 mas.% navedene učinkovine in od 0.03 do 10 mas.% granulirnega sredstva.
- 38. Dozirna oblika po zahtevku 37, značilen po tem, da je navedeno granulirno sredstvo izbrano iz skupine, ki obstaja iz polivinilpirolidona, vode, alkohola, saharoze, hidroksil celuloze, in njihovih zmesi.
- 39. Vodna ali drugačna tekoča suspenzija delcev za oralno aplikacijo ki vsebuje učinkovito količino učinkovine z velikostjo trdnih delcev pod 200 μιη spojine po formuli II(II) pri čemer je srednja velikost navedenih delcev učinkovine nad 10 pm; in najmanj ene farmacevtsko sprejemljive kisline, pri čemer je pH suspenzije med 2 in 6. o n rto !»β ί9βΟ 3 Ί O ·> O "> O O > -> Ί ·> ·> "> > O > θ’» ·1 1 » '.! » 1 > > > 1 1 -> > -> Ί > -Ί ^ 1 ) 9
- 40. Suspenzija po zahtevku 39, značilna po tem, da nadalje obsega granulirno sredstvo.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/852,447 US5968961A (en) | 1997-05-07 | 1997-05-07 | Pharmaceutical compositions of tizoxanide and nitazoxanide |
| US08/887,810 US5856348A (en) | 1994-09-08 | 1997-07-03 | Method for treatment of trematodes with pharmaceutical compositions of tizoxanide and nitazoxanide |
| US08/887,809 US5965590A (en) | 1994-09-08 | 1997-07-03 | Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide |
| PCT/US1998/009229 WO1998050035A1 (en) | 1997-05-07 | 1998-05-06 | Pharmaceutical compositions of tizoxanide and nitazoxanide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SI20149A SI20149A (sl) | 2000-08-31 |
| SI20149B true SI20149B (en) | 2001-08-31 |
Family
ID=27420362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI9820037A SI20149B (en) | 1997-05-07 | 1998-05-06 | Pharmaceutical compositions of tizoxanide and nitazoxanide |
Country Status (34)
| Country | Link |
|---|---|
| EP (2) | EP1222921B1 (sl) |
| JP (1) | JP3739802B2 (sl) |
| KR (2) | KR100576646B1 (sl) |
| CN (2) | CN100515420C (sl) |
| AP (1) | AP1103A (sl) |
| AR (1) | AR057242A2 (sl) |
| AT (2) | ATE281166T1 (sl) |
| AU (1) | AU740022B2 (sl) |
| BG (2) | BG109365A (sl) |
| BR (1) | BR9808722A (sl) |
| CA (2) | CA2288003C (sl) |
| CZ (2) | CZ298270B6 (sl) |
| DE (2) | DE69809928T2 (sl) |
| DK (2) | DK1005342T3 (sl) |
| EA (2) | EA002908B1 (sl) |
| EE (1) | EE04870B1 (sl) |
| ES (2) | ES2232687T3 (sl) |
| GE (1) | GEP20032970B (sl) |
| HU (1) | HU229641B1 (sl) |
| IL (2) | IL132516A (sl) |
| IS (1) | IS2087B (sl) |
| LV (1) | LV12492B (sl) |
| ME (1) | ME00530B (sl) |
| NO (2) | NO313983B1 (sl) |
| NZ (2) | NZ513881A (sl) |
| OA (1) | OA11169A (sl) |
| PL (1) | PL193275B1 (sl) |
| PT (2) | PT1005342E (sl) |
| RO (1) | RO120605B1 (sl) |
| SI (1) | SI20149B (sl) |
| SK (2) | SK283947B6 (sl) |
| TR (1) | TR199902733T2 (sl) |
| UA (2) | UA57079C2 (sl) |
| WO (1) | WO1998050035A1 (sl) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2467321A1 (en) | 2004-05-14 | 2005-11-14 | Paul J. Santerre | Polymeric coupling agents and pharmaceutically-active polymers made therefrom |
| MX2008008723A (es) * | 2006-01-09 | 2008-09-26 | Romark Lab Lc | Tratamiento de la hepatitis viral. |
| MX381895B (es) * | 2009-02-13 | 2025-03-13 | Romark Laboratories Lc | Formulaciones farmaceuticas de liberacion controlada de nitazoxanida. |
| CN105853415A (zh) | 2009-05-12 | 2016-08-17 | 罗马克实验室有限公司 | 卤代烷基杂芳基苯甲酰胺化合物 |
| BRPI1014322A2 (pt) | 2009-06-26 | 2015-08-25 | Romark Lab Lc | Método para tratar infecção, e para interromper ou evitar a produção de partículas virais infecciosas, combinação, e, composição farmacêutica. |
| US9498441B2 (en) | 2012-01-27 | 2016-11-22 | Siegfried Rhein S.A. De C.V. | Nitazoxadine composition and process to prepare same |
| JP6633092B2 (ja) * | 2014-11-11 | 2020-01-22 | ロマーク ラボラトリーズ，リミティド カンパニー | チゾキサニド、その類似体又は塩のプロドラッグを用いる組成物及び治療方法 |
| EP3740494A4 (en) | 2018-02-02 | 2021-11-03 | Ripple Therapeutics Corporation | GLASS FORMULATIONS WITH STEROID DIMERS AND USES THEREOF |
| WO2019241376A1 (en) | 2018-06-14 | 2019-12-19 | The Trustees Of Columbia University In The City Of New York | Treatment of cognitive disorders using nitazoxanide (ntz), nitazoxanide (ntz) analogs, and metabolites thereof |
| WO2020154815A1 (en) | 2019-02-01 | 2020-08-06 | Ripple Therapeutics Corporation | Crystalline forms of dexamethasone dimers and uses thereof |
| US12509469B2 (en) | 2019-08-07 | 2025-12-30 | Ripple Therapeutics Corporation | Compositions and methods for the treatment of pain and dependence disorders |
| CA3176134A1 (en) | 2020-05-01 | 2021-11-04 | Ripple Therapeutics Corporation | Heterodimer compositions and methods for the treatment of ocular disorders |
| WO2022130406A1 (en) * | 2020-12-15 | 2022-06-23 | Cipla Limited | Inhalation composition of nitazoxanide or its derivatives for use in coronavirus disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1437800A (en) * | 1973-08-08 | 1976-06-03 | Phavic Sprl | Derivatives of 2-benzamido-5-nitro-thiazoles |
| US4315018A (en) * | 1978-12-07 | 1982-02-09 | Rossignol Jean F | Specific parasiticidal use of 2-benzamido-5-nitro-thiazole derivatives |
| US5387598A (en) * | 1994-04-13 | 1995-02-07 | Rossignol; Jean-Francois | Composition and galenic formulation suitable for combatting affections of the lower abdomen |
| US5578621A (en) * | 1994-09-08 | 1996-11-26 | Romark Lab Lc | Benzamide derivatives |
-
1998
- 1998-05-06 SI SI9820037A patent/SI20149B/sl not_active IP Right Cessation
- 1998-05-06 KR KR1020037011334A patent/KR100576646B1/ko not_active Expired - Fee Related
- 1998-05-06 HU HU0003330A patent/HU229641B1/hu not_active IP Right Cessation
- 1998-05-06 ES ES02002887T patent/ES2232687T3/es not_active Expired - Lifetime
- 1998-05-06 EP EP02002887A patent/EP1222921B1/en not_active Expired - Lifetime
- 1998-05-06 NZ NZ513881A patent/NZ513881A/xx not_active IP Right Cessation
- 1998-05-06 EA EA199901012A patent/EA002908B1/ru not_active IP Right Cessation
- 1998-05-06 NZ NZ500149A patent/NZ500149A/en not_active IP Right Cessation
- 1998-05-06 SK SK708-2003A patent/SK283947B6/sk unknown
- 1998-05-06 AU AU72895/98A patent/AU740022B2/en not_active Ceased
- 1998-05-06 CN CNB2004100459536A patent/CN100515420C/zh not_active Expired - Fee Related
- 1998-05-06 GE GEAP19985109A patent/GEP20032970B/en unknown
- 1998-05-06 SK SK1511-99A patent/SK283946B6/sk unknown
- 1998-05-06 AP APAP/P/1999/001675A patent/AP1103A/en active
- 1998-05-06 AT AT02002887T patent/ATE281166T1/de active
- 1998-05-06 DK DK98920285T patent/DK1005342T3/da active
- 1998-05-06 CN CNB988049007A patent/CN1158074C/zh not_active Expired - Fee Related
- 1998-05-06 ME MEP-2008-877A patent/ME00530B/me unknown
- 1998-05-06 WO PCT/US1998/009229 patent/WO1998050035A1/en not_active Ceased
- 1998-05-06 IL IL13251698A patent/IL132516A/xx not_active IP Right Cessation
- 1998-05-06 JP JP54843798A patent/JP3739802B2/ja not_active Expired - Fee Related
- 1998-05-06 CA CA002288003A patent/CA2288003C/en not_active Expired - Fee Related
- 1998-05-06 EE EEP199900578A patent/EE04870B1/xx unknown
- 1998-05-06 CA CA002418634A patent/CA2418634C/en not_active Expired - Fee Related
- 1998-05-06 AT AT98920285T patent/ATE228839T1/de active
- 1998-05-06 PT PT98920285T patent/PT1005342E/pt unknown
- 1998-05-06 EA EA200100956A patent/EA002920B1/ru not_active IP Right Cessation
- 1998-05-06 CZ CZ20060366A patent/CZ298270B6/cs not_active IP Right Cessation
- 1998-05-06 RO RO99-01166A patent/RO120605B1/ro unknown
- 1998-05-06 DE DE69809928T patent/DE69809928T2/de not_active Expired - Lifetime
- 1998-05-06 KR KR10-1999-7009930A patent/KR100426657B1/ko not_active Expired - Lifetime
- 1998-05-06 EP EP98920285A patent/EP1005342B1/en not_active Expired - Lifetime
- 1998-05-06 PT PT02002887T patent/PT1222921E/pt unknown
- 1998-05-06 TR TR1999/02733T patent/TR199902733T2/xx unknown
- 1998-05-06 BR BR9808722-3A patent/BR9808722A/pt not_active IP Right Cessation
- 1998-05-06 ES ES98920285T patent/ES2150404T3/es not_active Expired - Lifetime
- 1998-05-06 DE DE69827417T patent/DE69827417T2/de not_active Expired - Lifetime
- 1998-05-06 PL PL336805A patent/PL193275B1/pl not_active IP Right Cessation
- 1998-05-06 DK DK02002887T patent/DK1222921T3/da active
- 1998-05-06 IL IL15579998A patent/IL155799A/en not_active IP Right Cessation
- 1998-05-06 CZ CZ0391199A patent/CZ298269B6/cs not_active IP Right Cessation
- 1998-06-05 UA UA99126626A patent/UA57079C2/uk unknown
- 1998-12-06 BG BG109365A patent/BG109365A/en unknown
-
1999
- 1999-10-19 IS IS5223A patent/IS2087B/is unknown
- 1999-10-29 OA OA9900239A patent/OA11169A/en unknown
- 1999-11-04 NO NO19995406A patent/NO313983B1/no not_active IP Right Cessation
- 1999-12-01 LV LVP-99-170A patent/LV12492B/en unknown
- 1999-12-06 BG BG103958A patent/BG64973B1/bg unknown
-
2002
- 2002-04-18 NO NO20021832A patent/NO335781B1/no not_active IP Right Cessation
-
2003
- 2003-04-04 UA UA2003042974A patent/UA74388C2/uk unknown
-
2006
- 2006-12-14 AR ARP060105534A patent/AR057242A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6326360B1 (en) | Bubbling enteric coated preparations | |
| US7122204B2 (en) | Antibiotic composition with inhibitor | |
| US4665081A (en) | Solid nifedipine preparations and a process for preparing same | |
| JP4832045B2 (ja) | メキタジン、イブプロフェン及びトラネキサム酸含有医薬組成物 | |
| DK0620731T3 (da) | Farmaceutisk præparat i form af en bruse- og/eller henfaldstablet eller et instantgranulat samt fremgangsmåde til fremstilling deraf | |
| JPH05262651A (ja) | 向精神薬の安定化溶液 | |
| JP2016503030A (ja) | 医薬組成物 | |
| HUP0300854A2 (hu) | Magas koncentrációjú stabil meloxicam oldatok | |
| US20170231988A1 (en) | Pharmaceutical Composition of Rosuvastatin Calcium | |
| SK281441B6 (sk) | Použitie 2-amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzotiazolu | |
| BG65324B1 (bg) | Фармацевтична форма за еднократно дневно перорално приложение на кларитромицин | |
| EP1089731A1 (en) | Compositions and methods for treating elevated blood cholesterol | |
| DE60042168D1 (de) | Chronotherapeutische diltiazem formulierungen und deren verabreichung | |
| JP2023520845A (ja) | ヒドロキシクロロキン及び／又はクロロキンを含む経口送達システム | |
| WO2004028567A1 (ja) | 薬物吸収性改善剤 | |
| NL8900734A (nl) | Vaste, snel uiteenvallende toedieningsvormen. | |
| AU623731B2 (en) | Water dispersible gemfibrozil compositions | |
| AR057242A2 (es) | Composicion farmaceutica para administracion oral y uso de la misma en la fabricacion de un medicamento | |
| ES2648338T3 (es) | Composiciones farmacéuticas de raltegravir, procedimientos para su preparación para su uso | |
| DE60035579D1 (de) | Multipartikuläre arzneizusammensetzungen mit gesteuerter wirkstoffabgabe enthaltend selektive inhibitoren der serotoninwiederaufnahme | |
| JP2003171313A (ja) | 医薬組成物 | |
| RS50685B (sr) | Koncentrovani vodeni rastvor ambroksola | |
| JPH07173057A (ja) | イブプロフェン含有粒剤 | |
| EP1328274A1 (en) | Compositions containing an inhibitor of dihydrofolate reductase and a folate | |
| EP0522006A1 (en) | Compositions comprising cytotoxic agent and permeation enhancers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| IF | Valid on the event date | ||
| KO00 | Lapse of patent |
Effective date: 20130108 |